HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Doppler flow analysis of the palmaris superficial branch of the radial artery in postmenopausal women with acroparesthesia: the role of hormone therapy. A pilot study
Method Twenty-three patients with acroparesthesia were su bmi tted to clinical evaluation and color Doppler analysis of the uterine artery and palmaris superficial branch of the radial artery . Thirteen women ( Group I ) were su bmi tted to hormone treatment with drospirenone 2 mg + + estradiol emidrate 1 mg .  Ten patients refused the treatment and served as controls ( Group II ) . The patients were studied at baseline and after 6 months ' therapy . Results After 6 months of hormone therapy , the resistances of the uterine artery and palmaris superficial branch of the radial artery significantly decreased in Group I patients . This was associated with the complete disappearance of paresthesic symptoms in 12/13 ( 92%% ) of the treated patients . In patients belonging to Group II , the paresthesia remained unchanged . Conclusion Hormone therapy with drospirenone may increase the forearm/h and blood flow , and favor the amelioration of paresthesia
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .